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ABSTRACT
Objective: To investigate the relationship between the
prevalence of smoking in the population and incidence
of invasive meningococcal disease (IMD) among
children under 5 years of age.
Design: Retrospective, longitudinal, observational
study. Poisson regression controlled for confounding
factors.
Setting: Norway, Sweden, Denmark and the
Netherlands between 1975 and 2009.
Population: Total population of approximately
35 million people in these four countries.
Data sources: Data were collected from the Ministries
of Health, National Statistics Bureaus and other
relevant national institutes.
Results: In Norway, there was a significant positive
relationship between the annual prevalence of daily
smokers among individuals aged 25–49 years and the
incidence of IMD in children under 5 years of age,
unadjusted (RR=1.04–1.06, 95% CI 1.02 to 1.07,
p<0.001) and after adjustment for time of year
(quarter), incidence of influenza-like illness and
household crowding (RR=1.05–1.07, 95% CI 1.03 to
1.09, p<0.001). Depending on age group, the risk of
IMD increased by 5.2–6.9% per 1% increase in
smoking prevalence among individuals aged 25–
49 years in adjusted analyses. Using limited datasets
from the three other countries, unadjusted analysis
showed positive associations between IMD in children
related to older smokers in Sweden and the
Netherlands and negative associations related to
younger smokers in Sweden. However, there were no
demonstrable associations between incidence of IMD
and prevalence of smoking, after adjustment for the
same confounding variables.
Conclusions: The reduced incidence of IMD in
Norway between 1975 and 2009 may partly be
explained by the reduced prevalence of smoking during
this period. High-quality surveillance data are required
to confirm this in other countries. Strong efforts to
reduce smoking in the whole population including
targeted campaigns to reduce smoking among adults
may have a role to play in the prevention of IMD in
children.
INTRODUCTION
Invasive meningococcal disease (IMD) caused
by the bacterium Neisseria meningitidis is a
major cause of septicaemia and meningitis glo-
bally, with a case-fatality rate of 5–10% and sig-
niﬁcant sequelae in approximately 20% of
survivors.1–4 The incidence of IMD in Europe
is 1–27/100 000/year in 1–4-year-olds,5 6 and
IMD is the leading infectious cause of early
childhood death in the UK. The peak age of
disease incidence in Europe is among children
Strengths and limitations of this study
▪ This is the first study to investigate the relation-
ship between smoking and invasive meningococ-
cal disease (IMD) using population-based data.
▪ We have been able to estimate population attrib-
utable risk, and identified risk associated with
particular age groups.
▪ The dataset from Norway enabled robust statis-
tical analysis to assess a potential association
between IMD in children >5 years of age and
daily smoker rate.
▪ Datasets from Sweden, Denmark and the
Netherlands were more limited and did not allow
for a comprehensive analysis.
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aged between 6 months and 2 years. N. meningitidis,
however, is carried asymptomatically in the nasopharynx
of approximately 10% of the population, with highest car-
riage rates among 15–25-year-olds.7 8 Transmission of bac-
teria occurs by direct contact with nasal or oral secretions
or through inhalation of large droplet nuclei.9 Factors
which affect transmission, acquisition or invasion of bac-
teria will, therefore, inﬂuence rates of invasive disease.
A number of factors which inﬂuence the anatomy or
physiology of the nasopharynx have been associated with
an increased risk of IMD, including time of year (peaks
in winter and spring), special climatic conditions (eg,
dry season and dust storm), concurrent respiratory tract
infection and smoking.1 10 In addition, active smoking8
11–14 and exposure to second-hand smoke8 15–17 have
been associated with an increased risk of carriage of
N. meningitidis. Multivariate analyses from case–control
studies suggested an association between exposure to
tobacco smoke and the risk of meningococcal disease
and/or carriage,18–23 with ORs of up to 9.1 in children
under 6 years of age.19 In one study, 37% of IMD in chil-
dren was attributed to maternal smoking,22 and a dose–
response effect between smoking and IMD has also
been suggested.22
The overall prevalence of smoking has declined sig-
niﬁcantly during the past 30 years in industrialised coun-
tries.24 The introduction of smoking bans in public
places in a number of countries worldwide has demon-
strated that there is a political will to sustain this trend.
During this time, Norway and the Netherlands experi-
enced hyperendemic IMD, but there has been a marked
reduction in incidence in both countries during the last
decade. Sweden and Denmark have had a relatively low
incidence of IMD throughout this period. All four coun-
tries introduced smoking bans between 1988 and 2007.
While there are a large number of case–control studies
identifying smoking as a risk factor for IMD, there are
limited data to investigate if there is any relationship at a
population level, and to, therefore, establish if interven-
tions to reduce smoking would have any impact on the
incidence of IMD.
METHODS
Selection of confounding variables
The primary study objective was to assess the relationship
between the prevalence of smoking and incidence of IMD
in children <5 years between 1975 and 2009. The rationale
behind selecting children <5 years was that the highest
incidence of IMD in Europe occurs among this age
group.5 Potential confounding variables to be included in
the statistical analysis were initially identiﬁed by PubMed
searches, references from relevant articles and the reports
of health agencies of relevant countries. PubMed search
terms were “neisseria”, “meningitidis”, “meningococcal”,
“meningitis”, “septicaemia”, “smoking”, “tobacco”, “expos-
ure”, “environmental”, “risk”, “association”, “multivariate”,
“odds ratio” and “protection”. A number of factors
associated with altered risk of IMD were identiﬁed. Those
considered for inclusion were independently associated
with meningococcal disease and/or carriage in a multivari-
ate analysis with an OR of ≥2 or ≤0.5 and demonstrated
biological plausibility18–23 25–29 (see online supplementary
table S1). Of these, data were available from all countries
for rates of inﬂuenza-like illness (ILI) and levels of house-
hold crowding, which were subsequently included in the
analyses. The only protective risk factors identiﬁed accord-
ing to these criteria in the case–control studies were men-
ingococcal vaccination29 and attendance at religious
ceremonies,29 of which the latter was not adjusted for due
to the age group in consideration. Meningococcal vaccin-
ation was only relevant to the Netherlands due to imple-
mentation of a serogroup C meningococcal vaccine in
2001, and this was taken into account. In Norway, there is
no routine immunisation against meningococcal disease,
but a clinical trial with a serogroup B vaccine was per-
formed with 180 000 Norwegian teenagers in 1988–1991.
However, the vaccinated individuals were 14–16 years of
age at the time of vaccination.30 Since this age group does
not frequently mix with children of <5 years of age31 and
there is no apparent effect on carriage, previous meningo-
coccal vaccination was, therefore, not taken into account.
Definitions
The incidence of IMD was based on the number of
laboratory-conﬁrmed cases per year per 100 000 chil-
dren in the population prior to their ﬁfth birthday.
Laboratory conﬁrmation was based on a positive bacter-
ial culture in blood or cerebrospinal ﬂuid, with the add-
itional use of PCR from 1999 (Norway), 2002 (Sweden),
2003 (the Netherlands) or 2005 (Denmark). Annual
smoking prevalence was measured using the percentage
of the population who were regular daily smokers, cate-
gorised by 5–10-year-age bands and gender wherever
these data were available. An overcrowded household
was deﬁned as a household containing more than one
person per room (excluding kitchen and bathroom for
all countries and also excluding living rooms in
Sweden). In Norway and Denmark, a single person
living in one room was also deﬁned as an overcrowded
household. In Norway and the Netherlands, weekly rates
of ILI were measured per 100 000 population based on
the data from sentinel surveillance centres. In Sweden
and Denmark, the proportion of all consultations which
were for ILI among the surveillance centres was used.
For Sweden, laboratory data on the number of con-
ﬁrmed inﬂuenza isolates were used as these data were
available from 1994, whereas data on consultation rates
were only available from 2001. Comparison of data from
2001 to 2009 showed good correlation between the two
datasets (R2=0.73 by linear regression analysis, data from
n=246 weeks, p<0.001, data not shown), and relying on
laboratory-conﬁrmed cases of inﬂuenza justiﬁed the use
of the laboratory-based data in our statistical model.
Additional country-speciﬁc issues are described below.
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Data sources
Norway, Sweden, Denmark and the Netherlands were
selected for study due to the high quality of surveillance
for IMD and smoking prevalence over a long period of
time. The smoking prevalence data were obtained by
surveys among representative selections of the popula-
tion in the four different target countries. The study
countries are also comparable in terms of socio-
economic equality, as measured by income distribution
(Gini-coefﬁcient <30 for all; OECD). For each dataset in
each country, the public organisation responsible for
surveillance was asked to provide the most detailed data
available, some of which were already in the public
domain (eg, published on relevant organisation
website). In some cases, additional data were obtained
from independent sources to enable robust analyses
(table 1).
The Netherlands introduced routine infant immunisa-
tion with a meningococcal serogroup C conjugate
vaccine in September 2002, so this analysis only included
cases of non-serogroup C disease. Surveillance methods
for estimation of ILI incidence in Norway did change
during the study period, and have been described previ-
ously.33 Brieﬂy, between 1975 and 1998 all general prac-
tices and outpatient emergency clinics were obliged to
report episodes of ILI. Rates of ILI were calculated as a
proportion of the total population, without adjusting for
the reporting coverage. From 1998, there were 201 senti-
nel reporting units located throughout Norway used to
calculate incidence rates.
Statistical methods
Poisson regression models were used to estimate inci-
dence rate ratios, with and without adjustment for time
(annually for Denmark, Sweden and the Netherlands,
or quarterly for Norway), ILI and household crowding
using Stata V.11 (StataCorp, College Station, Texas,
USA). These estimate the average relative change in
IMD incidence per unit increase in smoking prevalence.
Each analysis was performed over the longest time
period for which all relevant data were available, so in
some cases, adjusted analyses covered shorter durations
than unadjusted analyses. Separate models were ﬁtted
for each country and for every age-speciﬁc and gender-
speciﬁc group of smokers where data were available.
The analyses were repeated using the Generalised
Estimating Equation (GEE) method to account for the
autocorrelation structure of the data. The results were
similar to those obtained from the Poisson regression
model, and therefore are not reported here. The meth-
odology for calculating the population-attributable risk
was performed as previously described.34
For Norway, quarterly data were used for incidence of
IMD and an assumption was made that smoking preva-
lence and crowding rates were constant for each quarter
of a year. In addition, ILI data for Norway were trans-
formed to allow for the different reporting systems
before and after 1998. Three low-incidence inﬂuenza
seasons with the old reporting system (pre-1998) and
three with the new system (post-1998) were selected,
and the average number of cases reported per season in
the pre-1998 seasons was divided by the average number
of cases for the three post-1998 seasons. Every data point
was then multiplied by this factor to calculate a standar-
dised ILI rate which could be used throughout the study
period.
Imputation was performed when ILI and crowding
data were not available. For simpliﬁcation of analysis,
missing values were assumed to be missing at random.
In order to avoid a loss in efﬁciency missing values for
ILI were imputed using multiple imputation by chained
equations.35 Ten imputed datasets were created by
replacing missing values with simulated values from a set
of imputation models built from all potential prognostic
variables (smoking prevalence, household crowding and
ILI rate) and the outcome variable (incidence of IMD).
Poisson regression analysis was performed on each
imputed dataset and the imputation-speciﬁc coefﬁcients
were combined using Rubin’s rules.36 ‘Year’ and
‘Quarter’ terms were included in the model as linear
terms to take into account linear trends over time.
RESULTS
Data availability
Annual incidence of IMD in children under 5 years of
age and a measure of the yearly prevalence of smoking
in each country were available for all countries for most
of the study period, with the most complete datasets
obtained from Norway and the Netherlands (table 1).
Data for overcrowding were the most difﬁcult to obtain
due to the infrequent and inconsistent methods used
for its estimation. All data were included in the analyses,
except crowding data from the Netherlands due to the
lack of sufﬁcient data points.
Norway
The incidence of IMD in children under 5 years of age
in Norway increased from 1977 to 1983–1984 with an
incidence of 25–45/100 000/year, and then declined
steadily to <5/100 000/year after 2004 (ﬁgure 1). The
prevalence of daily smokers decreased over the same
time period in all age groups, from 25–49% to 13–26%,
depending on the age group (ﬁgure 1). There was a sig-
niﬁcant positive association between incidence of IMD
and prevalence of smoking in the unadjusted analysis,
with an increase of 2.7–5.7% in IMD incidence per 1%
rise in prevalence of daily smokers (table 2). The popu-
lation attributable risk per cent ranged from 1% to 1.9%
for the age groups with a signiﬁcant association in the
unadjusted analysis, totalling 11.4% for these seven
groups (table 2).
During the study period, there was a steady decline in
household crowding, from 16% of the population living
in a crowded household in 1980 down to 6% in 2007
(ﬁgure 2). In contrast, the rate of ILI remained
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Table 1 Data sources and availability
Data item Target dataset
Country
Norway Sweden Denmark The Netherlands
Incidence of invasive
meningococcal
disease
Annual incidence in children
<5 years of age
NIPH
Quarterly incidence
<5 years,
1977–2009
National reference Laboratory
for Pathogenic Neisseria
Annual incidence all ages,
1975–2009 (<5 years from
1997)
Department of
Epidemiology, Statens
Serum Institut
Annual incidence
<5 years, 1975–2007
The Netherlands
Reference Laboratory for
Bacterial Meningitis
Annual incidence <5 years,
1980–2009
Prevalence of
smoking*
Annual percentage of population
who are daily smokers (ideally
age-specific and gender-specific)
Norwegian
Directorate for
Health
Annual
age-specific data,
1975–2009
National Institute of Public
Health
Annual age-specific and
gender-specific data, 1980–
2007
OECD and ISS
Annual gender-specific
data, 1975–2008
OECD and STIVORO
Annual gender-specific
data, 1975–2009
Rate of ILI Weekly consultation rate among
sentinel centres for ILI during
influenza season (weeks 1–20
and 40–52)
NIPH
Weekly rate,
1975–2009
Department of Epidemiology,
Swedish Institute for
Communicable Disease
Control†
Weekly rate, 1994–2009
Statens Serum Institut
Weekly rate, 1994–2009
NIVEL
Weekly rate, 1975–2009
Overcrowding Annual percentage of population
living in a crowded household
Statistics Norway
Data every
2–4 years,
1980–2007
Statistics Sweden
Data every 2 years, 1980–2007
Statbank Denmark,
Statistics Denmark
Annual data, 1981–2009
Central Bureau of Statistics
Data every 3–5 years,
1981–2009
*Based on survey data on self-reported status of smoking.
†Based on laboratory-confirmed cases of ILI rather than consultation rate due to greater availability of data.
ISS, International Smoking Statistics32; ILI, influenza-like illness; NIPH, Norwegian Institute of Public Health, Oslo, Norway; NIVEL, The Netherlands Institute for Health Services Research,
Utrecht, The Netherlands (www.nivel.nl); OECD, Organisation for Economic Co-operation and Development (www.oecd.org); STIVORO, Stichting Volksgezondheid en Roken, Den Haag, The
Netherlands (http://www.stivoro.nl).
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relatively constant, other than the usual seasonal vari-
ation. The apparent abrupt change in 1998 coincided
with a change in the method of data collection, which
was corrected for in the analysis. The pre-1998 system
ended in week 20 of 1998, whereas the post-1998 system
started in week 40 of 1998. The distribution of the cov-
ariates is shown in online supplementary table S2. After
adjusting for ILI and household crowding, a positive
association remained between incidence of IMD in
children <5 years and prevalence of smoking in the
population for all age groups between 25 and 59 years,
except the 50–54 years group (table 3). There was an
increase of 2.5–6.9% in IMD incidence per 1% rise in
prevalence of daily smokers.
Sweden
The incidence of IMD in children <5 years was only
available from 1997 onwards, limiting analysis that was
Figure 1 Trends of incidence of invasive meningococcal disease in children <5 years of age and prevalence of daily smokers in
Norway (A and B), Sweden (C and D), Denmark (E and F) and the Netherlands (G and H) between 1975 and 2009. Incidence of
invasive meningococcal disease (IMD) in children <5 years of age is shown in (A), (C), (E) and (G). Percentage of population
who are daily smokers is in (B), (D), (F) and (H). For Sweden, additional data illustrating the incidence of IMD in all age groups is
depicted in the grey line, due to the limited availability of data for children <5 years of age. For the Netherlands, data for
non-serogroup C disease only are shown. For Norway, smoking data for the 30–34 years of age group are shown. For Sweden,
smoking data for the 35–44 years male group are shown. For Denmark and the Netherlands, data for males only are shown. In
all countries age groups and genders not shown followed similar trends. The incidence of IMD has decreased in children in all
four countries since the 1990s, and in Norway throughout the study period. The prevalence of smoking has decreased in all four
countries during the study period.
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possible within the target age group. Nevertheless, there
was a decrease in the incidence of IMD in this group
between 1997 and 2009 from 1.76 to 1.46/100 000/year.
A similar trend was apparent during the same time
period for smoking prevalence in all age and gender
groups (ﬁgure 1). The relative decrease in smoking
prevalence was between 25.7% (in 16–24-year-old men)
and 47% (in 35–44-year-old women). In all age and
gender groups, these trends in smoking prevalence were
occurring from 1980. In the unadjusted analysis, there
was an increased risk of IMD in children <5 years related
to smokers aged 35–54 years, whereas a reduced risk was
seen related to smokers aged 16–34 years (table 2).
Adjustment for household crowding and ILI could only
be performed on data between 1997 and 2009, and
there was no signiﬁcant relationship between smoking
and IMD in this limited analysis. Data on overall inci-
dence of IMD were, however, available from 1980, and
since there was a high correlation between the overall
IMD incidence (all ages) and incidence of IMD in chil-
dren <5 years of age for the years when both were mea-
sured, an additional analysis was performed using these
data. After adjustment for household crowding, there
Table 2 Unadjusted age-specific and sex-specific relative risk of IMD in children aged <5 years according to annual
percentage of daily smokers in different genders age groups in Norway, Sweden, Denmark and the Netherlands between
1975 and 2009
Country and years Age group (years) Gender
Relative risk of IMD
associated with a 1%
increase in prevalence
of smoking (95% CI) p Value
Population
attributable risk (%)
Norway
1977–2009
16–19 M, F 0.99 (0.98 to 1.00) 0.155 −0.2
20–24 M, F 1.01 (1.00 to 1.03) 0.185 0.3
25–29 M, F 1.04 (1.02 to 1.06) <0.001* 1.4
30–34 M, F 1.05 (1.04 to 1.06) <0.001* 1.8
35–39 M, F 1.05 (1.03 to 1.06) <0.001* 1.9
40–44 M, F 1.06 (1.04 to 1.07) <0.001* 2.1
45–49 M, F 1.06 (1.04 to 1.07) <0.001* 2.2
50–54 M, F 1.01 (1.00 to 1.03) 0.123 0.3
55–59 M, F 1.03 (1.01 to 1.04) <0.001* 1
≥60 M, F 1.04 (1.02 to 1.06) <0.001* 1
Sweden
1993–2007
16–24 M 0.95 (0.93 to 0.98) <0.001* −0.8
F 0.96 (0.94 to 0.98) <0.001* −0.9
25–34 M 0.98 (0.96 to 0.99) 0.007* −0.5
F 1.02 (1.00 to 1.04) 0.119 0.5
35–44 M 1.07 (1.04 to 1.10) <0.001* 1.8
F 1.05 (1.03 to 1.07) <0.001* 1.4
45–54 M 1.01 (1.00 to 1.04) 0.214 0.3
F 1.04 (1.03 to 1.06) <0.001* 1.1
55–64 M 0.94 (0.92 to 0.97) <0.001* −1.6
F 0.99 (0.97 to 1.01) 0.434 −0.2
Denmark
1975–2007
≥15 M 1.00 (0.95 to 1.06) 0.947 0
F 0.94 (0.88 to 1.02) 0.135 −1.7
The Netherlands
1980–2009†
15–19 M, F 1.01 (0.96 to 1.06) 0.797 0.2
20–34 M, F 0.99 (0.92 to 1.07) 0.860 −0.4
35–49 M, F 1.13 (1.08 to 1.19) <0.001* 4.5
The proportion of IMD cases in the total population that can be attributed to smoking (population attributable risk per cent) per age group and
gender is also shown.
*Statistically significant (p<0.05) association between prevalence of smoking and incidence of IMD in children <5 years of age.
†Age-specific data on daily smoker prevalence in the Netherlands were prepared by combining data from OECD (1975–2009), ISS (1975–
1995) and demographic data, and were only available over time for groups of individuals aged 15–19, 20–34 and 35–49 years.
IMD, invasive meningococcal disease.
Figure 2 Percentage of the population living in a crowded
household during 1980–2007 in Norway. Data retrieved from
Statistics Norway (http://www.ssb.no).
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was a signiﬁcant association between overall incidence of
IMD and prevalence of smoking in all groups, except
smoking prevalence in 55–64-year-old women (table 4).
There was no clear-cut relationship, since some smoking
age groups appeared to confer an increased risk of IMD
and others a reduced risk.
Denmark and the Netherlands
Similar patterns of IMD incidence were observed in both
of these countries, with initial increase in incidences
before a subsequent decrease. The incidence peaks were
in 1987 in Denmark and 1998 in the Netherlands. Both
countries experienced a steady decrease in prevalence of
smoking between 1975 and 2008–2009 (ﬁgure 1). There
were no signiﬁcant associations between incidence of
IMD and prevalence of smoking in the unadjusted ana-
lysis in Denmark (table 2), although age-speciﬁc data on
smoking prevalence were not available. In the
Netherlands, unadjusted analyses showed a signiﬁcant
association between IMD in children <5 years of age and
daily smoker rate among individuals aged 35–49 years of
age, but were not signiﬁcant after adjustment for ILI and
household crowding. Adjustment for overcrowding could
not be performed with the dataset from the Netherlands
due to lack of sufﬁcient data points.
DISCUSSION
Main findings
This study provides further evidence that exposure to
tobacco smoke is an independent risk factor which
increases the risk of IMD. Of the four countries studied,
the most complete dataset for IMD, smoking, ILI and
household crowding was obtained from Norway. Over a
34-year period, a 5.2–6.9% increase in IMD in children
under 5 years of age was observed for every 1% rise in
prevalence of smoking in adults aged between 25 and
49 years. Taken together with previous case–control
studies showing smoking as a risk factor for contracting
IMD, the reduction in smoking prevalence that has
occurred in Norway during this period is likely to have
made a signiﬁcant contribution to the concurrent reduc-
tion in incidence of IMD. The proportion of IMD cases
under 5 years of age in the total population that could
be attributed to active smoking in Norway was found to
be 11.4%, which is far lower than that estimated in
other studies for young children.22 37 The lack of dem-
onstrable associations between incidence of IMD and
prevalence of smoking, after adjustment for the same
confounding variables, in Denmark, Sweden and the
Netherlands may in part be ascribed to the limited data-
sets available. The absence of statistically signiﬁcant asso-
ciations is hence difﬁcult to interpret, although
unadjusted analysis showed positive associations between
IMD in children related to older smokers in Sweden and
the Netherlands. In contrast, negative associations were
found related to younger smokers in Sweden. These
mixed patterns of associations may indicate that not all
biologically relevant confounding factors were
accounted for.
Strengths and limitations
This study has allowed exploration of the relationship
between IMD and exposure to tobacco smoke using an
approach that has not previously been considered. The
study provides a long-term, population-based observa-
tional study over a 30-year time period that we believe is
valuable to provide evidence of the longitudinal
Table 4 Adjusted relative risk of invasive meningococcal
disease in children and adults (all ages included)
according to annual percentage of daily smokers in
different genders and age groups in Sweden between
1980 and 2007, after adjustment for year and household
crowding
Age
group
(years) Gender
Relative risk of IMD
associated with a 1%
increase in prevalence
of smoking (95% CI) p Value
16–24 M 0.93 (0.90 to 0.95) <0.001*
F 0.94 (0.91 to 0.96) <0.001*
25–34 M 0.97 (0.95 to 0.99) 0.002*
F 1.05 (1.01 to 1.08) 0.005*
35–44 M 1.11 (1.07 to 1.15) <0.001*
F 1.07 (1.04 to 1.10) <0.001*
45–54 M 1.04 (1.00 to 1.08) 0.043*
F 1.06 (1.04 to 1.09) <0.001*
55–64 M 0.95 (0.93 to 0.98) 0.004*
F 1.01 (0.98 to 1.04) 0.376
*Statistically significant (p<0.05) association between prevalence
of smoking and incidence of IMD
IMD, invasive meningococcal disease; F, female; M, male.
Table 3 Adjusted relative risk of invasive meningococcal
disease in children aged <5 years according to annual
percentage of daily smokers in different age groups in
Norway between 1977 and 2007, after adjustment for
quarter, influenza-like illness and household crowding
Age group
(years)
Relative risk of IMD
associated with a 1% increase
in prevalence of smoking
(95% CI) p Value
16–19 1.00 (0.98 to 1.01) 0.582
20–24 1.01 (0.99 to 1.03) 0.301
25–29 1.05 (1.03 to 1.07) <0.001*
30–34 1.05 (1.04 to 1.07) <0.001*
35–39 1.06 (1.05 to 1.08) <0.001*
40–44 1.07 (1.05 to 1.08) <0.001*
45–49 1.07 (1.05 to 1.09) <0.001*
50–54 1.01 (1.00 to 1.03) 0.117
55–59 1.03 (1.01 to 1.04) <0.001*
≥60 1.04 (1.01 to 1.06) 0.002*
*Statistically significant (p<0.05) association between prevalence
of smoking and incidence of IMD in children <5 years of age.
IMD, invasive meningococcal disease.
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association between smoking and IMD, while previous
evidence was primarily based on case–control studies
and biological model studies. Furthermore, we have pro-
vided estimates of population-attributable risk, and iden-
tiﬁed risk associated with particular age groups. The
study highlights the relevance of long-term monitoring
of infectious disease risk factors and standardised report-
ing formats between countries. The existence of surveil-
lance systems in some European countries with
databases which, to a large extent, could be interrogated
historically back to the 1970s has allowed observation of
trends not only for incidence of IMD and prevalence of
smoking over 34 years, but also correction for the major
confounding variables of household crowding and ILI.
The Norwegian dataset was reasonably complete, allow-
ing for a comprehensive analysis to assess a potential
association between IMD in children <5 years of age and
daily smoker rate, whereas the available datasets for
Sweden, Denmark and the Netherlands were more
limited. For Sweden, there were no data available on
IMD incidence in children <5 years of age for the
period prior to 1997, and no data on ILI rates prior to
1994. The change in IMD incidence in children <5 years
of age during the relatively short period for which a full
dataset was available was also relatively minor. Hence,
the apparent lack of association may also have been
impacted by the limitations in data availability. This was
also the case for the data from the Netherlands and
Denmark, where data were not as comprehensive as
from Norway where the completeness of the dataset was
high apart from data on crowding. Speciﬁcally, for the
Netherlands, there was insufﬁcient information to
include an adjustment for household crowding, and
there was a lack of age-speciﬁc data on smoking prior to
1995. For Denmark, there was insufﬁcient frequency of
age-speciﬁc data on smoking, and no data on ILI rates
prior to 1994. The analyses performed here within
should be repeated at a later time point, when longer
time series of full datasets are available from Denmark,
Sweden and the Netherlands. Analyses were performed
over the longest possible period with consistent data col-
lection methods. In Norway, there was a change in ascer-
tainment of ILI during the study period, and this was
corrected for in the analysis in consultation with those
responsible for collecting the data. There was unfortu-
nately no time period in which both collection methods
were used, hence in order to ensure one full time series
dataset, we bridged the datasets by a transformation pro-
cedure as described above. We cannot rule out that this
may have confounded the assessment of the association
between the variables.
The accuracy of smoking prevalence data obtained by
self-report surveys has been discussed in the scientiﬁc lit-
erature,38 as there may be inaccuracy due to misreport-
ing of smoking status and the failure to include
non-cigarette tobacco smoking.38 Using the measure-
ment of the nicotine-derived metabolite cotinine in bio-
logical ﬂuids as a marker of tobacco exposure in
individuals, studies have found that the self-reported
status of smoking may underestimate the true tobacco
exposure. In this study, we could not determine any vari-
ability in exposure measurement error over time.
However, it is often reported that the level of inaccuracy
is low.38 In the current study, the self-reported survey
method was used for all countries over the whole time
period to measure the daily smoker prevalence, and the
association studies performed were hence not likely to
be severely affected by this.
The major limitation of the study was the availability of
data for ILI and household crowding in terms of duration
and frequency of data collection, requiring some imput-
ation. Differences found between countries may simply be
a reﬂection of data availability, or may represent true dif-
ferences. As with any analysis of association between two
variables over such a long time period, there may be a
number of confounding variables for which it was not pos-
sible to completely adjust. Speciﬁc to meningococcal
disease, most previously described risk factors relate to
closeness of contact or preceding illness. Although adjust-
ing based on ILI and household crowding would account
for many related factors, there may be additional confoun-
ders which we were not able to include in the analysis,
such as exposure to a person from jail, recent analgesia
use and attendance on religious ceremonies.21 23 29
Additional factors such as differential effects of the patho-
gens responsible for ILI33 or degree of household crowd-
ing were not considered due to lack of data. During the
study period, a number of other changes in society may
have occurred, including changes in diet and exercise
habits, socialisation behaviour and antimicrobial usage,
which may inﬂuence the rate of IMD. These changes are,
however, more difﬁcult to quantify due to lack of time-
series data and were therefore not included in our statis-
tical models. An association between meteorological vari-
ables (ie, temperature and humidity) and the prevalence
of acute respiratory tract infections (ARIs) has been docu-
mented,39 and some studies suggest an association
between ARIs and meningococcal disease.40–42 Changes in
meteorological variables (eg, average winter temperature)
may affect the invasion of meningococci across the epithe-
lial barrier and hence the incidence of meningococcal
disease, and should be further studied. In this study, we
have included ILI as a confounding factor; however, other
causes of ARIs were not included due to a lack of time-
series data. Over time, the incidence of meningococcal
disease does naturally ﬂuctuate within a population due to
multiple possible mechanisms, but consideration of a long
period in this study makes the results less likely to be
affected by such ﬂuctuations. Although it is not possible to
rule out other factors directly or indirectly being respon-
sible for the association found in this study (eg, meteoro-
logical variables), concurrence with multiple case–control
studies which include extensive multivariate analyses adds
to the evidence base showing an association between IMD
and smoking. Since these were population level data and
we were able to adjust for gender and age at population
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level, it is, however, not possible to draw conclusions about
the effect at an individual level (ecological fallacy) as the
danger of using ecological studies to draw biological infer-
ence in public health has been well documented due to
the potential disconnection between the level of inference
and the level of analysis.43
In this study, we did not stratify on N. meningitidis gen-
otypes due to the lack of consistent genotyping data over
the whole study period. This may affect short-term ﬂuc-
tuations in incidence since the initiation of an epidemic
is thought to occur by the introduction of a hyperviru-
lent clone into a susceptible population,44 whereas the
waning of an meningococcal epidemic over years follow-
ing a peak is hypothesised to be due to an increasing
immunity against the epidemic clone in the general
population.45 The hyperinvasive meningococcal strain
types that caused the epidemic waves in Norway (ST-32
clonal complex) and the Netherlands (ST-41/44 clonal
complex) seem to have minimal lifespans of 36 and
26 years, respectively.45 It could be hypothesised that
when a sufﬁcient proportion of an immunologically sus-
ceptible population are daily smokers, the spread of a
newly introduced virulent strain is far more successful.
This is supported by the ﬁnding that elevated carriage
levels being more likely to occur in a population with a
high rate of daily smokers. One moderating factor is that
the case to carrier rate varies between the different
hyperinvasive strain types. Ultimately, there may also be
unknown factors needed to trigger an epidemic that our
analysis did not account for.
Comparison with other studies
Although there are a number of case–control studies
which have shown exposure to tobacco smoke to be a sig-
niﬁcant risk factor for meningococcal disease and car-
riage, this is the ﬁrst study to demonstrate the association
at a population level, which therefore has major public
health implications. A large number of previous case–
control studies have found exposure to tobacco smoke to
be a major risk factor for carriage of N. meningitidis as
well as invasive disease. Studies investigating the associ-
ation of smoking with IMD have been performed
throughout Europe, North America and Australasia, and
generally considered exposure to tobacco smoke in the
2–4 weeks prior to disease.18–23 25–29 The children who
had a parent or carer who smoked, particularly if the
smoker was the mother, were most strongly associated
with IMD. Although some clear trends are apparent from
these studies, there are several limitations. First, different
measures have been used to estimate exposure to tobacco
smoke. If tobacco smoke increases the risk of IMD by pro-
moting meningococcal carriage in teenagers and young
adults, then the number of smoker contacts would be the
most important factor. If, however, there is a direct effect
of tobacco smoke increasing the risk of bacterial invasion,
then overall exposure to smoke should be considered.
Both mechanisms may play a role, and there is undoubt-
edly a confounding effect between these two factors. We
have used prevalence of daily smokers as a measure of
exposure to tobacco smoke, which primarily reﬂects
number of smoker contacts, and also overall exposure to
smoke. In addition, the age groups considered in past
studies are not consistent, with tobacco smoke appearing
to be a risk factor for IMD primarily in younger children.
A further problem is that many studies suggest that an
association exists, but the ORs/RRs do not reach signiﬁ-
cance due to the small number of IMD cases and rela-
tively low proportion of smokers, and many studies do
not include a multivariate analysis. In those studies where
a multivariate analysis has been carried out, different con-
founding factors are included in the models, making it
difﬁcult to compare. A recent meta-analysis found that
second-hand exposure to tobacco smoke was associated
with a signiﬁcantly increased risk of IMD with an OR of
2.02 (95% CI 1.52 to 2.69).46 In the three studies speciﬁc-
ally addressing pre-school children (≤6 years), the associ-
ation was stronger, but non-signiﬁcant (OR=3.04, 95% CI
0.89 to 10.47), most likely due to inadequate power even
with the combined analysis. The population-level
approach used in our study complements previous case–
control studies and supports the same conclusion that
exposure to tobacco smoke does adversely inﬂuence the
risk of IMD.
Humans are the sole reservoir for N. meningitidis, with
asymptomatic carriage of the organism occurring in the
nasopharynx. In a small number of individuals, bacteria
invade into the bloodstream and thereafter the central
nervous system. The risk for a young child of developing
IMD is, therefore, dependent on factors which affect
acquisition of the organism (eg, contact patterns, car-
riage rates of contacts and environmental factors, includ-
ing exposure to tobacco smoke18 19 22) combined with
factors which inﬂuence invasion (eg, strain virulence,
host immunity and integrity of the nasopharyngeal
mucosal surface). The age relationship between primary
and secondary cases of meningococcal disease47 closely
resembled the patterns found in studies of physical con-
tacts.31 Young children are mostly in close contact with
other children of the same age and adults aged 20–
44 years, presumably representing the demographics of
parents and carers.31 48 Anything which signiﬁcantly
affects meningococcal carriage in this age group would,
therefore, have a high impact on transmission, and
therefore incidence of invasive disease, in young chil-
dren. Carriage rates of N. meningitidis were elevated
among smokers compared with non-smokers in a
number of studies from Europe, the USA, New Zealand
and Burkina Faso, with rates usually 2–3 times higher in
smokers.8 11–17 49 50 Tobacco smoke also affects integrity
of the nasopharyngeal mucosa and host immunity in
general.51 Both may affect the risk of invasion of a colo-
nising organism, and the former may also result in an
altered risk of acquisition through changes in the
expression of adhesion molecules on the epithelial cell
surface and the cytokine milieu, which may favour bac-
terial invasion.52
Norheim G, Sadarangani M, Omar O, et al. BMJ Open 2014;4:e003312. doi:10.1136/bmjopen-2013-003312 9
Open Access
group.bmj.com on October 27, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
Structural changes in the respiratory tract that have
been attributed to tobacco smoke include peribronchio-
lar inﬂammation and ﬁbrosis, increased mucosal perme-
ability, impairment of mucociliary clearance, changes in
pathogen adherence and disruption of the respiratory
epithelium,52 53 which are thought to predispose indivi-
duals to the development of respiratory tract infections.
While the nasopharyngeal ﬂora of smokers may contain
fewer normal commensal bacteria and more potential
pathogens than seen among non-smokers,54 tobacco
smoke can also affect cell-mediated and humoral
immune responses in humans and animals.53 Smoking
can also be a fetal determinant for IMD, as shown in a
Danish case–control study ﬁnding associations between
low birth weight (<2500 g) and risk for IMD (OR 1.5,
95% CI 1.0 to 2.3), and between maternal smoking and
IMD.55 56 The elevated risk for IMD persisted throughout
early childhood. This adds to previous studies showing
that maternal smoking during pregnancy and environ-
mental tobacco smoke exposure during pregnancy are
associated with low birth weight.57 The proportion of chil-
dren born in Norway with low birth weight (<2500 g) was,
however, relatively stable in the period 1975–2008 (5.2–
6.4%) (http://www.norgeshelsa.no).
Implications for practice and conclusions
We have demonstrated a statistically signiﬁcant, inde-
pendent association between incidence of IMD in chil-
dren under 5 years of age and the prevalence of
smoking at the population level in Norway, supporting
results of case–control studies, as well as animal data and
in vitro biological studies. This is, therefore, highly likely
to represent the causation rather than just association.
The observed decline in IMD incidence over the past
30–40 years in a number of high-income countries
worldwide may, therefore, be at least partly explained by
a reduction in smoking. These data suggest that
smoking in the parental age group has the biggest inﬂu-
ence on disease in young children, consistent with
known contact patterns of these children and transmis-
sion dynamics of N. meningitidis. To verify whether the
association between IMD and smoking in Norway is
reproducible in other settings, similar studies should be
performed in regions with a high rate of daily smokers.
For this to be enabled, it is vital that countries collect
high-quality data not only on IMD and smoking, but also
on possible confounding variables of this interaction to
allow future prospective analysis to be undertaken to
conﬁrm our ﬁndings. Efforts to reduce smoking should
be considered as an essential component of public
health measures to reduce meningococcal disease, in
addition to other speciﬁc interventions such as routine
immunisation.
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